Gene therapy: Gene therapy with p53 virus (gendicine) and hyperthermia provides dramatic improvements in patients with advanced cancer shows small (15 participants) phase II study. Article posted in July 2007

July 1, 2007: Source: 1: Int J Hyperthermia. November 2005, 21 (7) :631-6.

Gene therapy with adenovirus p53 (also known as Gendicine) combined with hyperthermia provides excellent results in patients with advanced cancer. 13 of the 15 participating patients had many treatments without success behind them and were basically incurable. 2 patients also had advanced cancer but still had no treatment before. Here, a literal translation of the abstract of the study. Below a link to how the Dutch government on gene therapy in China thinks that after a committee has probed. What is strikingly positive. Plus two links to more information about gene therapy

The treatment achieved a complete response so the cancer was clinically road (with scans confirmed) in two patients, partial response = more than 50% of the tumors had disappeared clinically. Stable disease, no progression in eight patients and in only one patient there was progression of the disease. After treatment in two patients the tumors disappeared yet and in 7 of the 13 remaining patients showed the density (LDA) of more than 50% tumor area on CT scans. No patient experienced severe behandelignsgeraleerde bijwekringe, at most some fever after Adp53 administration. Conclusion: Adp53 combined with hyperthermia was safe and efectief in patients with advanced cancer. The p53 gene therapy was potentially heat sensitive in advanced cancer.

Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases).
Zhang S, Xu G, Liu C, Xiao S, Sun Y, Su X, Cai Y, Li D, Xu B. Department of Radiotherapy, School of Oncology, Beijing University, Vol. 52, Fu-Cheng Road, Hai Dian District, Beijing 100036, PR China. The study was zhangshw@yeah.net to Evaluate the efficacy of the Adp53 combined with hyperthermia on advanced cancer. Fifteen Patients with advanced cancer Were enrolled in this clinical trial. Thirteen Patients with recurrent tumoren Conventional treatments failed and in the primary tumor with Two Other patiënten Received no treatment before They Were enrolled. Recombinant adenovirus-p53 (Adp53) is a substituted E1 replication-incompetent recombinant adenovirus encoding the human wild-type p53 (wtp53) gene. Were the 15 patients injected with intra-tumourally Adp53, 1x10 (12) vp (virus particle) once a week, with a total of 4-8 times was Given. The temperature being set hyperthermia everytime week 3 days after the injection of Adp53 at 43-44 degrees C. Using 915 MHz microwave machine for superficial tumor for 1 h or at 42-43 degrees C. Using 41 MHz radiofrequency machine for deep-seated tumor for a h. Among the 15 patients, five concurrently with radiotherapy and added Were Were added three with cisplatin-based chemotherapy. The treatment Achieved CR in two cases, PR in four cases, SD in eight cases and PD in one case and, after the treatment, or tumoren Disappeared two cases and seven of the Other 13 cases (54%) had low-density area ( LDA) or More Than 50% on CT images in tumoren. In the 15 patients, no dose-limiting toxicity and adverse events noted Were, The except transient fever after Adp53 administration. In Conclusion, Adp53 combined with hyperthermia was safe and effective in patient with advanced cancer and p53 gene therapy was to thermosensitize potential in advanced cancer.

PMID: 16304714 [PubMed - indexed for MEDLINE]

The Dutch government gendicine writes about gene therapy and the following: Gendicine gene therapy and gene therapy by commission and then signaling to the bottom of page for full report

Here's some additional information on gene therapy (gendicine):

Noorderlicht VPRO on gene therapy

Gene Information

Gentherpaie information